Share This Article:

Splenic Marginal Zone Lymphoma in a Patient with Positive Hepatitis B Virus Serology*

Abstract Full-Text HTML XML Download Download as PDF (Size:115KB) PP. 105-107
DOI: 10.4236/ojbd.2013.34021    4,093 Downloads   7,892 Views  

ABSTRACT

We present a case in which an elderly woman diagnosed with a splenic marginal zone lymphoma (MZL) was found to have positive Hepatitis B serology. Link with Hepatitis C virus is well documented but reports of association of Hepatitis B virus (HBV) with splenic marginal zone lymphoma are still emerging. A 69-year-old lady presented with weight loss, pancytopenia and marked splenomegaly. Prior to commencing treatment, Hepatitis B serology confirmed Hepatitis B infection. She was treated with Chlorambucil along with anti-hepatitis B prophylaxis and HBV PCR monitoring. She had an excellent response to treatment with resolution of symptoms and splenomegaly. This case highlights the importance of testing for hepatitis B serology in patients diagnosed with splenic MZLs as causative agent. Although the association between HCV is well documented in the literature, a relationship between HBV may also be important. Also, chemotherapy +/- Rituximab for splenic MZL is associated with the reactivation of latent infections; hence providing prophylactic cover for pre-existing latent HBV infection may be required to prevent reactivation as in this case.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Q. Iman, E. Dewi and B. Syed, "Splenic Marginal Zone Lymphoma in a Patient with Positive Hepatitis B Virus Serology*," Open Journal of Blood Diseases, Vol. 3 No. 4, 2013, pp. 105-107. doi: 10.4236/ojbd.2013.34021.

References

[1] C. Thieblemont, F. Davi, M. E. Noguera, J. Brière, F. Bertoni, E. Zucca, et al., “Splenic Marginal Zone Lymphoma: Current Knowledge and Future Directions,” Oncology (Williston Park), Vol. 26, No. 2, 2012, pp. 194-202.
[2] M. Mollejo, F. I. Camacho, P. Algara, E. Ruiz-Ballesteros, J. F. García and M. A. Piris, “Nodal and Splenic Marginal Zone B Cell Lymphomas,” Hematological Oncology, Vol. 23, No. 3-4, 2005, pp. 108-118.
http://dx.doi.org/10.1002/hon.762
[3] L. Arcaini, M. Lazzarino, N. Colombo, S. Burcheri, E. Boveri, M. Paulli, et al., “Integruppo Italiano Linfomi; Splenic Marginal Zone Lymphoma: A Prognostic Model for Clinical Use,” Blood, Vol. 107, No. 12, 2006, pp. 4643-4649. http://dx.doi.org/10.1182/blood-2005-11-4659
[4] C. Montalbán, V. Abraira, L. Arcaini, E. Domingo-Do- menech, P. Guisado-Vasco, E. Iannito, et al., “Splenic Marginal Zone Lymphoma Study Group. Risk Stratification for Splenic Marginal Zone Lymphoma Based on Haemoglobin Concentration, Platelet Count, High Lactate Dehydrogenase Level and Extrahilar Lymphadenopathy: Development and Validation on 593 Cases,” British Journal of Haematology, Vol. 159, No. 2, 2012, pp. 164-171. http://dx.doi.org/10.1111/bjh.12011
[5] J. Peveling-Oberhag, G. Crisman, A. Schmidt, C. Doring, M. Lucioni, L. Arcaini, et al., “Dysregulation of Global MicroRNA Expression in Splenic Marginal Zone Lymphoma and Influence of Chronic Hepatitis C Virus Infection,” Leukemia, Vol. 26, No. 7, 2012, pp. 1654-1662.
http://dx.doi.org/10.1038/leu.2012.29
[6] S. S. Chuang, Y. L. Liao, S. T. Chang, Y. C. Hsieh, S. Y. Kuo, C. L. Lu, et al., “Hepatitis C Virus Infection Is Sig- nificantly Associated with Malignant Lymphoma in Taiwan, Particularly with Nodal and Splenic Marginal Zone Lymphomas,” Journal of Clinical Pathology, Vol. 63, No. 7, 2010, pp. 595-598.
[7] B. Szynglarewicz, R. Matkowski, Z. Smorag, J. Forgacz, M. Pudelko and J. Kornafel, “Hepatitis C Virus Infection and Locally Advanced Splenic Marginal Zone Lymphoma,” Pathology and Oncology Research, Vol. 13, No. 4, 2007, pp. 382-384.
http://dx.doi.org/10.1007/BF02940322
[8] G. E. Gurvits, R. Mahtani and I. Halperin, “Hepatitis C Virus and Splenic Marginal Zone Lymphoma with Villous Lymphocytes: Away from Conventional Therapy,” Scandinavian Journal of Gastroenterology, Vol. 42, No. 11, 2007, pp. 1392-1393.
http://dx.doi.org/10.1080/00365520701420800
[9] J. Svoboda, C. Andreadis, L. H. Downs, W. T. Miller Jr., D. E. Tsai and S. J. Schuster, “Regression of Advanced Non-Splenic Marginal Zone Lymphoma after Treatment of Hepatitis C Virus Infection,” Leuk Lymphoma, Vol. 46, No. 9, 2005, pp. 1365-1368.
http://dx.doi.org/10.1080/104281905001028289
[10] L. Arcaini, S. Burcheri, A. Rossi, M. Paulli, R. Bruno, F. Passamonti, et al., “Prevalence of HCV Infection in Non-gastric Marginal Zone B-Cell Lymphoma of MALT,” Annals of Oncology, Vol. 18, No. 2, 2007, pp. 346-350.
http://dx.doi.org/10.1093/annonc/mdl388
[11] L. Christou, G. Kalambokis, M. Bai, S. Kamina and E. V. Tsianos, “Splenic Marginal Zone Lymphoma in a Patient with Chronic Hepatitis B,” Journal of Gastrointestinal and Liver Diseases, Vol. 18, No. 4, 2009, pp. 511-512.
[12] E. Gómez-de la Fuente, L. B. Villalón, L. Calzado-Villarreal, F. Pinedo-Moraleda and J. L. López-Estebaranz, “Splenic Marginal Zone B-Cell Lymphoma with Epidermotropic Skin Involvement,” Actas Dermosifiliogr, Vol. 103, No. 5, 2012, pp. 427-431.
http://dx.doi.org/10.1016/j.ad.2011.06.004
[13] S. H. Zhang, A. M. Xu, J. M. Zheng and M. X. He, “Coexistence of Splenic Marginal Zone Lymphoma with Hepatocellular Carcinoma: A Case Report,” Diagnostic Pathology, Vol. 2, 2007, p. 5.
http://dx.doi.org/10.1186/1746-1596-2-5
[14] K. Fujimoto, T. Endo, M. Nishio, M. Obara, K. Yamaguchi, Y. Takeda, et al., “Complete Remission of Splenic Marginal Zone Lymphoma after an Acute Flare-Up of Hepatitis B in a Hepatitis B Virus Carrier,” International Journal of Hematology, Vol. 90, No. 5, 2009, pp. 601-604. http://dx.doi.org/10.1007/s12185-009-0426-y
[15] S. Kusumoto, Y. Tanaka, R. Ueda and M. Mizokami, “Reactivation of Hepatitis B Virus Following Rituximab-Plus-Steroid Combination Chemotherapy,” Journal of Gastroenterology, Vol. 46, No. 1, 2011, pp. 9-16.
http://dx.doi.org/10.1007/s00535-010-0331-4
[16] S. Kusumoto, Y. Tanaka, M. Mizokami and R. Ueda, “Clinical Significance of Hepatitis B Virus (HBV)-DNA Monitoring to Detect HBV Reactivation after Systemic Chemotherapy,” Journal of Clinical Oncology, Vol. 29, No. 4, 2011, p. e100.
http://dx.doi.org/10.1200/JCO.2010.33.0332
[17] C. Kalpadakis, G. A. Pangalis, M. N. Dimopoulou, T. P. Vassilakopoulos, M. C. Kyrtsonis, P. Korkolopoulou, et al., “Rituximab Monotherapy Is Highly Effective in Splenic Marginal Zone Lymphoma,” Hematological Oncology, Vol. 25, No. 3, 2007, pp. 127-131.
http://dx.doi.org/10.1002/hon.820
[18] E. Zucca, A. Conconi, D. Laszlo, A. López-Guillermo, R. Bouabdallah, B. Coiffier, et al., “Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients with Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study,” Journal of Clinical Oncology, Vol. 31, No. 5, 2013, pp. 565-572.
http://dx.doi.org/10.1200/JCO.2011.40.6272

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.